89bio, Inc. is a clinical-stage biopharmaceutical company developing therapies for liver and cardiometabolic diseases. The company is headquartered in the United States with operations in Israel.
Its lead program, pegozafermin, is a long-acting analog of the endogenous hormone FGF21 in clinical development for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) and severe hypertriglyceridemia (SHTG). Pegozafermin is engineered to extend half-life and enhance biological activity to address key drivers of these conditions, including dyslipidemia, insulin resistance, inflammation, and fibrosis.
Roche's subsidiary accepted tendered shares of 89bio, planning a merger to make 89bio a wholly owned subsidiary, delisting it from Nasdaq.
Tender offer expires Oct 29, 2025. Includes CVR up to $6.00. Requires majority share tender, no financing condition. Second-step merger follows at same terms. Completion expected Q4 2025.
Roche enhances its CVRM portfolio with 89bio's pegozafermin, targeting MASH. The deal is valued up to $3.5 billion, with potential milestone payments. Completion expected Q4 2025.
